


Amendments to the Claims

The following listing of claims replaces all prior versions of listing of claims in the application:

1. (Currently Amended) A pharmaceutical composition, comprising: a compound of formula (1) in solid form:



(1)

together with a pharmaceutically acceptable carrier or excipient,


provided that the compound of formula (1) is present in polymorphic Form A ~~and is substantially free of other polymorphic forms.~~

2. (Currently Amended) The pharmaceutical composition of claim 1 in which the compound of formula (1) is present as orthorhombic crystals.
3. (Currently Amended) The pharmaceutical composition of claim 1, which is formulated as ~~in the form of~~ a tablet or capsule.
4. (Cancelled)
5. (Currently Amended) The pharmaceutical composition of claim 1, wherein ~~at least about 90% of~~ the compound of formula (1) exhibits no PXRD peaks of polymorphic forms B and C at about is polymorphic Form A, as defined by PXRD peak heights around 9° 2-theta.
6. (Currently Amended) The pharmaceutical composition of claim 1, further comprising

lactose and microcrystalline cellulose.

7. (Original) The tablet of claim 3, which weighs between 250 and 500 mg.

8. (Currently Amended) A solid composition comprising isolated crystals of the compound of formula (1)



(1)

in which said crystals ~~the isolated crystals of compound (1)~~ are present in polymorphic Form A and ~~substantially free of other polymorphs~~.

9. (Original) The composition of claim 8, wherein ~~the isolated~~ said crystals of compound (1) are present as orthorhombic crystals.

10. (Cancelled)

11. (Currently Amended) The composition of claim 8, wherein ~~the isolated~~ said crystals exhibit no PXRD peaks of polymorphic forms B and C at about ~~are at least about 90%~~ polymorphic Form A, as defined by PXRD peak heights around 9° 2-theta.

12. (Cancelled)